Literature DB >> 33275045

Methods for the discovery of small molecules to monitor and perturb the activity of the human proteasome.

Marianne E Maresh1, Andres F Salazar-Chaparro1, Darci J Trader1.   

Abstract

Regulating protein production and degradation is critical to maintaining cellular homeostasis. The proteasome is a key player in keeping proteins at the proper levels. However, proteasome activity can be altered in certain disease states, such as blood cancers and neurodegenerative diseases. Cancers often exhibit enhanced proteasomal activity, as protein synthesis is increased in these cells compared with normal cells. Conversely, neurodegenerative diseases are characterized by protein accumulation, leading to reduced proteasome activity. As a result, the proteasome has emerged as a target for therapeutic intervention. The potential of the proteasome as a therapeutic target has come from studies involving chemical stimulators and inhibitors, and the development of a suite of assays and probes that can be used to monitor proteasome activity with purified enzyme and in live cells.

Entities:  

Keywords:  degradation; proteasome; screening

Mesh:

Substances:

Year:  2020        PMID: 33275045      PMCID: PMC7857359          DOI: 10.4155/fmc-2020-0288

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  93 in total

Review 1.  Proteasome dysregulation in human cancer: implications for clinical therapies.

Authors:  Yulin Chen; Yanan Zhang; Xing Guo
Journal:  Cancer Metastasis Rev       Date:  2017-12       Impact factor: 9.264

2.  Monitoring the Immunoproteasome in Live Cells Using an Activity-Based Peptide-Peptoid Hybrid Probe.

Authors:  Breanna L Zerfas; Darci J Trader
Journal:  J Am Chem Soc       Date:  2019-03-20       Impact factor: 15.419

3.  Neuronal induction of the immunoproteasome in Huntington's disease.

Authors:  Miguel Díaz-Hernández; Félix Hernández; Ester Martín-Aparicio; Pilar Gómez-Ramos; María A Morán; José G Castaño; Isidro Ferrer; Jesús Avila; José J Lucas
Journal:  J Neurosci       Date:  2003-12-17       Impact factor: 6.167

4.  Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

Authors:  Deborah J Kuhn; Sally A Hunsucker; Qing Chen; Peter M Voorhees; Marian Orlowski; Robert Z Orlowski
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

5.  Screening bicyclic peptide libraries for protein-protein interaction inhibitors: discovery of a tumor necrosis factor-α antagonist.

Authors:  Wenlong Lian; Punit Upadhyaya; Curran A Rhodes; Yusen Liu; Dehua Pei
Journal:  J Am Chem Soc       Date:  2013-08-01       Impact factor: 15.419

6.  Protein stability and resistance to oxidative stress are determinants of longevity in the longest-living rodent, the naked mole-rat.

Authors:  Viviana I Pérez; Rochelle Buffenstein; Venkata Masamsetti; Shanique Leonard; Adam B Salmon; James Mele; Blazej Andziak; Ting Yang; Yael Edrey; Bertrand Friguet; Walter Ward; Arlan Richardson; Asish Chaudhuri
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-17       Impact factor: 11.205

Review 7.  Aim for the core: suitability of the ubiquitin-independent 20S proteasome as a drug target in neurodegeneration.

Authors:  Kwadwo A Opoku-Nsiah; Jason E Gestwicki
Journal:  Transl Res       Date:  2018-06-19       Impact factor: 7.012

Review 8.  The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders.

Authors:  Breanna L Zerfas; Marianne E Maresh; Darci J Trader
Journal:  J Med Chem       Date:  2019-11-21       Impact factor: 7.446

Review 9.  The ubiquitin proteasome system in glia and its role in neurodegenerative diseases.

Authors:  Anne H P Jansen; Eric A J Reits; Elly M Hol
Journal:  Front Mol Neurosci       Date:  2014-08-08       Impact factor: 5.639

10.  A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers.

Authors:  Tiffany A Thibaudeau; Raymond T Anderson; David M Smith
Journal:  Nat Commun       Date:  2018-03-15       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.